167 results on '"Capitain O"'
Search Results
2. Rehabilitation following total laryngectomy: Oncologic, functional, socio-occupational and psychological aspects
3. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
4. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors
5. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
6. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
7. Facteurs influençant le retour au travail et le maintien en emploi après un cancer du sein
8. Valeur pronostique du volume tumoral métabolique sur la TEP au (18F)-fluorodésoxyglucose préthérapeutique pour le cancer de l’œsophage localisé
9. Des marges extensives sont-elles nécessaires pour la radiothérapie du cancer de l’œsophage ?
10. Sites de récidive après radiothérapie conformationnelle avec modulation d’intensité des carcinomes épidermoïdes des voies aérodigestives supérieures
11. 1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
12. Évolution des cancers de l’œsophage : impact de la stratégie thérapeutique
13. Apport de la TEP-FDG dans le staging initial des cancers du sein localement avancés traités par chimiothérapie néo-adjuvante
14. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study
15. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)
16. Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study
17. 70P Outcomes in patients treated with taxane regimen after immune checkpoint inhibitors failure in advanced or metastatic non-small cell lung cancer
18. P-136 Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients
19. 425P Cetuximab could be administered once every two weeks instead of once weekly
20. 481P Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer
21. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
22. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer
23. 1617P PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
24. Pharmacogénétique des anticancéreux
25. Apports de la pharmacogénomique et de la pharmacogénétique dans les cancers digestifs
26. 5-fluorouracile : MSI, pharmacocinétique, DPD, TYMS et MTHFR
27. Évaluation d’un pronostic clinique de 2 mois chez des patients atteints d’un cancer du sein : les premiers résultats de l’étude Pronopall...
28. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
29. L’élévation persistante de la vitamine B12 plasmatique comme marqueur prédictif de cancer solide
30. Étude de phase 1 d’escalade de dose d’irradiation avec modulation d’intensité et boost intégré simultané dans la chimioradiothérapie pelvienne des cancers du bas et moyen rectum métastatiques synchrones
31. Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials
32. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
33. PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)
34. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
35. Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method
36. EP-1138: Laser Therapy for radiochemotherapy-induced mucositis in HNC: a randomised, phase III trial
37. Traitement des mucites radio- et chimio-induites par laser de basse énergie en cancérologie ORL : résultats de l’essai de phase III randomisé multicentrique « Laser mucite ORL »
38. The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit
39. 1110O - Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials
40. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer
41. 781TiP - PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)
42. P-216 - Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method
43. 1050PD - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit
44. Analysis of Genome Alterations in Head and Neck Squamous Cell Carcinoma to Identify Potential Prognosis Biomarkers or Targetable Genetic Aberrations
45. A Triple Combination Tailored Therapy (Folfiri-Cetuximab) for Safe Dose Intensification: A Multicenter Phase II Proof-Of-Concept Study.
46. Évaluation en pratique courante de l’association bevacizumab-FOLFIRI en première ligne chez des patients atteints d’un cancer colorectal métastatique non résécable traités en 2006: focus sur patients réséqués et oncogériatrie
47. Forme pseudo-tumorale de radionécrose cérébrale, à propos d’un cas
48. Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study
49. EP-1067: Non metastatic esophagus cancer: outcome according to therapeutic strategy.
50. Rhabdomyome multifocal et tomographie par émission de positons
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.